2,2',2''-(10-((S)-6-((4R,7S,10S,13S,16S,19R,22S,25S,28R)-19-((1H-indol-3-yl)methyl)-16-(4-aminobutyl)-10,22,25-tribenzyl-4-carboxy-13-((R)-1-hydroxyethyl)-7-(hydroxymethyl)-6,9,12,15,18,21,24,27-octaoxo-1,2-dithia-5,8,11,14,17,20,23,26-octaazacyclononacosan-28-ylcarbamoyl)-1-amino-1-imino-8,17-dioxo-10,13-dioxa-2,7,16-triazaoctadecan-18-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid (Compound)

Description: A compound in the knowledge graph

Analyze

CFDE DD-Knowledge Graph

The CFDE Data Distillery Knowledge Graph contains entities and relationships across the CFDE. View 2,2',2''-(10-((S)-6-((4R,7S,10S,13S,16S,19R,22S,25S,28R)-19-((1H-indol-3-yl)methyl)-16-(4-aminobutyl)-10,22,25-tribenzyl-4-carboxy-13-((R)-1-hydroxyethyl)-7-(hydroxymethyl)-6,9,12,15,18,21,24,27-octaoxo-1,2-dithia-5,8,11,14,17,20,23,26-octaazacyclononacosan-28-ylcarbamoyl)-1-amino-1-imino-8,17-dioxo-10,13-dioxa-2,7,16-triazaoctadecan-18-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid's neighborhood in the knowledge graph.

Submit

Knowledge Graph Assertions

Source	Relation	Target	Evidence
2,2',2''-(10-((S)-6-((4R,7S,10S,13S,16S,19R,22S,25S,28R)-19-((1H-indol-3-yl)methyl)-16-(4-aminobutyl)-10,22,25-tribenzyl-4-carboxy-13-((R)-1-hydroxyethyl)-7-(hydroxymethyl)-6,9,12,15,18,21,24,27-octaoxo-1,2-dithia-5,8,11,14,17,20,23,26-octaazacyclononacosan-28-ylcarbamoyl)-1-amino-1-imino-8,17-dioxo-10,13-dioxa-2,7,16-triazaoctadecan-18-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid Compound (Entity type)	Bioactivity Knowledge Graph Relation (Entity type)	Somatostatin receptor type 2 Protein (Entity type)	IC50
2,2',2''-(10-((S)-6-((4R,7S,10S,13S,16S,19R,22S,25S,28R)-19-((1H-indol-3-yl)methyl)-16-(4-aminobutyl)-10,22,25-tribenzyl-4-carboxy-13-((R)-1-hydroxyethyl)-7-(hydroxymethyl)-6,9,12,15,18,21,24,27-octaoxo-1,2-dithia-5,8,11,14,17,20,23,26-octaazacyclononacosan-28-ylcarbamoyl)-1-amino-1-imino-8,17-dioxo-10,13-dioxa-2,7,16-triazaoctadecan-18-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid Compound (Entity type)	Bioactivity Knowledge Graph Relation (Entity type)	Somatostatin receptor type 3 Protein (Entity type)	IC50
2,2',2''-(10-((S)-6-((4R,7S,10S,13S,16S,19R,22S,25S,28R)-19-((1H-indol-3-yl)methyl)-16-(4-aminobutyl)-10,22,25-tribenzyl-4-carboxy-13-((R)-1-hydroxyethyl)-7-(hydroxymethyl)-6,9,12,15,18,21,24,27-octaoxo-1,2-dithia-5,8,11,14,17,20,23,26-octaazacyclononacosan-28-ylcarbamoyl)-1-amino-1-imino-8,17-dioxo-10,13-dioxa-2,7,16-triazaoctadecan-18-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid Compound (Entity type)	Bioactivity Knowledge Graph Relation (Entity type)	Somatostatin receptor type 5 Protein (Entity type)	IC50
2,2',2''-(10-((S)-6-((4R,7S,10S,13S,16S,19R,22S,25S,28R)-19-((1H-indol-3-yl)methyl)-16-(4-aminobutyl)-10,22,25-tribenzyl-4-carboxy-13-((R)-1-hydroxyethyl)-7-(hydroxymethyl)-6,9,12,15,18,21,24,27-octaoxo-1,2-dithia-5,8,11,14,17,20,23,26-octaazacyclononacosan-28-ylcarbamoyl)-1-amino-1-imino-8,17-dioxo-10,13-dioxa-2,7,16-triazaoctadecan-18-yl)-1,4,7,10-tetraazacyclododecane-1,4,7-triyl)triacetic acid Compound (Entity type)	Bioactivity Knowledge Graph Relation (Entity type)	Somatostatin receptor type 4 Protein (Entity type)	IC50